2,2'-bis(di-tert-butylphosphino)biphenyl | 879904-89-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,2'-bis(di-tert-butylphosphino)biphenyl
• 英文别名: di(t-butyl)(2-biphenyl)phosphine；2,2'-bis(di-tert-butylphosphino)-1,1'-biphenyl；bis-di(tert-butyl)(2-biphenyl)phosphine；2-(di-tert-butylphosphino)biphenyl；ditert-butyl-[2-(2-ditert-butylphosphanylphenyl)phenyl]phosphane
• CAS: 879904-89-9
• 化学式: C₂₈H₄₄P₂
• 分子量: 442.605
• InChiKey: LMAJREOZDVKQCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2,2'-bis(di-tert-butylphosphino)biphenyl 、 sodium tetrachloroaurate(III) dihyrate 在 S(CH₂CH₂OH)2 作用下， 以 氯仿 、 水 为溶剂， 以99%的产率得到[(2,2'-bis(di-tert-butylphosphino)biphenyl)(AuCl)2]
  参考文献：
  名称：

  含2,2'-双（膦基）联苯配体的双阳离子双（金）π-烯烃配合物的合成与结构

  摘要：

  双键双（金）-联芳基膦π-烯烃络合物{（P-P）[Au（π-烯烃）] 2 } 2+ 2SbF 6 – [P-P = 2,2'-双（二叔丁基膦基） ）联苯; 从烯烃与（P–P）（AuCl）2和AgSbF 6的1：2混合物的反应中，以> 95％的产率分离出烯烃=异丁烯，[1-戊烯]，并通过NMR光谱和X射线晶体学进行了表征。

  DOI：

  10.1021/om200948z
• 作为试剂：
  描述：

  1-异丙基哌嗪 、 (2R)-1-[(3-bromophenyl)sulfonyl]-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 2,2'-bis(di-tert-butylphosphino)biphenyl 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 以100%的产率得到(2R)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1-{[3-(4-isopropylpiperazin-1-yl)phenyl]sulfonyl}-2-methylpiperazine
  参考文献：
  名称：

  Piperazine Sulfonamides as Potent, Selective, and Orally Available 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors with Efficacy in the Rat Cortisone-Induced Hyperinsulinemia Model

  摘要：

  11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) is the enzyme that converts cortisone to cortisol. Evidence suggests that selective inhibition of 11 beta-HSD1 could treat diabetes and metabolic syndrome. Presented herein are the synthesis, structure-activity relationship, and in vivo evaluation of piperazine sulfonamides as 11 beta HSD1 inhibitors. Through modification of our initial lead 5a, we have identified potent and selective 11 beta-HSD1 inhibitors such as 13q and 13u with good pharmacokinetic properties.

  DOI：

  10.1021/jm8004948

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021239885A1

  公开（公告）日：2021-12-02

  The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

  本发明涉及用于抑制NLRP3炎症体产生的新化合物，其中所述化合物由公式（I）定义，其中整数R1、R2和R3在描述中定义，且所述化合物可用作药物，例如用于治疗与NLRP3炎症体活性相关的一种疾病或失调。
• [EN] IDOLES USEFUL IN THE TREATMENT OF INFLAMMATION<br/>[FR] INDOLES UTILISES DANS LE TRAITEMENT DE L'INFLAMMATION
  申请人：BIOLIPOX AB

  公开号：WO2005005415A1

  公开（公告）日：2005-01-20

  There is provided a compound of formula (I), wherein X, Y, Z, R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or required, and particularly in the treatment of inflammation.

  提供一种化合物，其化学式为（I），其中X、Y、Z、R1、R2、R3、R4和R5的含义如描述中所述，并且其药用盐，这些化合物在治疗需要或期望抑制微粒体前列腺素E合成酶-1活性的疾病中非常有用，特别是在炎症治疗中。
• [EN] PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY<br/>[FR] PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACÉTAMIDES UTILISÉS EN TANT QU'INHIBITEURS DE LA VOIE DE L'INFLAMMASOME NLRP3
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021209539A1

  公开（公告）日：2021-10-21

  The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I), Formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

  该发明涉及用作NLRP3炎症小体产生抑制剂的新化合物，其中这些化合物由式(I)的化合物定义，式(I)中整数R1、R2和R3在描述中有定义，并且这些化合物可能作为药物有用，例如用于治疗与NLRP3炎症小体活性相关的疾病或疾病。
• NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS
  申请人：Pastor Fernández Joaquin

  公开号：US20130131057A1

  公开（公告）日：2013-05-23

  There is provided compounds of formula (I), wherein A 1 , A 4 , A 4a , A 5 , B 1 , B 1a , B 2 , B 2a , B 3 , B 3a , B 4 , B 4a and R 3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

  提供了式（I）的化合物，其中A1、A4、A4a、A5、B1、B1a、B2、B2a、B3、B3a、B4、B4a和R3在描述中给出了它们的含义，以及其药用可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要抑制蛋白质或脂质激酶（例如 PI3-K 和/或 mTOR）的疾病中是有用的，特别是在癌症或增殖性疾病的治疗中。
• IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS
  申请人：Pastor Fernández Joaquin

  公开号：US20120083492A1

  公开（公告）日：2012-04-05

  There is provided compounds of formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

  提供了式(I)的化合物，其中R1、R2、R3、R4和R5在描述中有给定的含义，以及它们的药用可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要或期望抑制蛋白质或脂质激酶（例如PI3-K和/或mTOR）的疾病方面非常有用，特别是在治疗癌症或增生性疾病方面。